Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
2期
进行中（已停止招募）
NCT02888743
| 适应症 | Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 |
|---|
| 分期 | 2期 |
|---|
| 申办方 | National Cancer Institute (NCI) |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 110 人 |
|---|
| 干预（药物） | Durvalumab, Radiation Therapy, Tremelimumab |
|---|
| 开始日期 | 2017年8月14日 |
|---|
| 完成日期 | 2023年12月31日 |
|---|
| 结果公布日 | 2024年6月25日 |
|---|
摘要
This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab and tremelimumab with radiation therapy may work better in treating patients with colorectal or non-small cell lung cancer.
Overall Response Rate
Up to 2 years · Participants
| NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT) | 3 Participants |
|---|
| NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT) | 2 Participants |
|---|
| NSCLC Arm C (Tremelimumab, Durvalumab) | 3 Participants |
|---|
| CRC Arm A (Tremelimumab, Durvalumab, HD-RT) | 0 Participants |
|---|
| CRC Arm B (Tremelimumab, Durvalumab, LD-RT) | 0 Participants |
|---|
| p-value | 0.99 |
|---|
| Difference between proportions | 0.0 (95% CI -14.6–14.6) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。